Serum Vascular Endothelial Growth Factor (VEGF) levels in patients with alpha thalassemia
Archives of Medical Laboratory Sciences,
Vol. 2 No. 1 (2016),
9 Farvardin 2016
https://doi.org/10.22037/amls.v2i1.14587
Abstract
Background: Alpha-thalassemia syndrome includes a group of hereditary anemia in which expression of alpha globin chains is decreased or absent. Impaired RBC in patients with thalassemia causes vessel involvement and endothelial cell vessel disturbance. Vascular Endothelial Growth Factor (VEGF) is the most important regulator for endothelial cell proliferation. So, the aim of this study is to compare the serum VEGF levels in patients with alpha thalassemia and normal control group.
Materials and Methods: This case-control study was conducted on 17 patients with alpha thalassemia and 40 healthy people. Serum VEGF levels were measured by enzyme-linked immune sorbent assay (ELISA) kit. Then statistical analysis of results were performed using SPSS 16, value of P <0.05 was considered statistically significant.
Results: Mean serum VEGF levels in case and control groups were 2294.19±1552.39 and 598.09±988.17pg/ml, respectively. Serum VEGF levels were higher in patients with alpha thalassemia (P <0.01). There was no significant correlation between serum VEGF levels and Hemoglobin. (P= 0.73).
Conclusion: Our study revealed that patients with alpha thalassemia have elevated levels of serum VEGF than normal control group. Further studies with larger sample size are recommended to confirm these observations.
- Alpha Thalassemia
- Vascular Endothelial Growth Factor(VEGF)
- Angiogenesis
How to Cite
References
Galanello R, Origa R. Beta-thalassemia. Orphanet journal of rare diseases. 2010;5(1):1.
Vichinsky EP. Clinical manifestations of α-thalassemia. Cold Spring Harbor perspectives in medicine. 2013;3(5):a011742.
Zarbakhsh B, Eghbalpour F, Farshadi E, Fallah M, Karimipoor M, Zeinali S. Frequency of alpha thalassemia carriers detected in Tehran premarriage screening using molecular techniques. Scientific Journal of Iranian Blood Transfusion Organization. 2013;9(4).
Origa R, Moi P, Galanello R, Cao A. Alpha-thalassemia. 2013.
Butthep P, Rummavas S, Wisedpanichkij R, Jindadamrongwech S, Fucharoen S, Bunyaratvej A. Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. American journal of hematology. 2002;70(2):100-6.
Shitrit D, Tamary H, Koren A, Levin C, Bargil-Shitrit A, Sulkes J, et al. Correlation of vascular endothelial growth factor with the severity of thalassemia intermedia. Blood Coagulation & Fibrinolysis. 2008;19(7):611-4.
Kofler NM, Simons M. Angiogenesis versus arteriogenesis: neuropilin 1 modulation of VEGF signaling. F1000prime reports. 2015;7.
Dunst J, Becker A, Lautenschläger C, Markau S, Becker H, Fischer K, et al. Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF). Strahlentherapie und Onkologie. 2002;178(8):436-41.
Fahmey SS, Naguib HF, Abdelshafy SS, Alashry RE. Vascular endothelial growth factor in children with thalassemia major. Mediterranean journal of hematology and infectious diseases. 2013;5(1).
Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nature medicine. 2003;9(6):669-76.
Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671-4.
Stone J, Itin A, Alon T, Pe'Er J, Gnessin H, Chan-Ling T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. The Journal of neuroscience. 1995;15(7):4738-47.
Ramakrishnan S, Anand V, Roy S. Vascular endothelial growth factor signaling in hypoxia and inflammation. Journal of Neuroimmune Pharmacology. 2014;9(2):142-60.
Olgar S, Kara A, Hicyilmaz H, Balta N, Canatan D. Evaluation of angiogenesis with vascular endothelial growth factor in patients with thalassemia major. Pediatrics International. 2010;52(2):247-51.
- Abstract Viewed: 606 times
- PDF Downloaded: 286 times